Clinical Trials Logo

Spindle Cell Rhabdomyosarcoma clinical trials

View clinical trials related to Spindle Cell Rhabdomyosarcoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT02567435 Active, not recruiting - Rhabdomyosarcoma Clinical Trials

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

Start date: June 1, 2016
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies how well combination chemotherapy (vincristine sulfate, dactinomycin, cyclophosphamide alternated with vincristine sulfate and irinotecan hydrochloride or vinorelbine) works compared to combination chemotherapy plus temsirolimus in treating patients with rhabdomyosarcoma (cancer that forms in the soft tissues, such as muscle), and has an intermediate chance of coming back after treatment (intermediate risk). Drugs used work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Combination chemotherapy and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether chemotherapy plus temsirolimus is more effective than chemotherapy alone in treating patients with intermediate-risk rhabdomyosarcoma.